Royalty Pharma (RPRX) announced the appointment of Carole Ho and Elizabeth Weatherman to its Board of Directors, effective immediately. Carole Ho is Chief Medical Officer and Head of Development at Denali Therapeutics (DNLI). Bess Weatherman is a Special Limited Partner of Warburg Pincus.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RPRX:
- Royalty Pharma price target raised to $54 from $51 at Morgan Stanley
- Strategic Financial Agreements and Promising Drug Developments Justify Buy Rating for Royalty Pharma
- Royalty Pharma’s Strategic Partnership with Revolution Medicines: A High-Reward Investment Opportunity
- Royalty Pharma announces $2B funding arrangement with Revolution Medicines
- Revolution Medicines enters $2B funding agreement with Royalty Pharma